The companies' new partnership could signal the beginning of the end for compounded GLP-1s.
Over a 24 week period, people on UBT251 lost up to 20% of their body weight on average.
The lawsuit is the latest in an escalating feud between the Danish pharmaceutical and telehealth company.
Novo Nordisk is worried about competition and wants to be seen as the cool kid... by using a 20-year-old ad format.
Man down in the Oval Office.
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent mandate. Hims pushed back against the accusation.
Lars Fruergaard Jørgensen is out.
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.
Dozens of obesity and diabetes treatments are in the pipeline, some of which may help people lose even more weight than existing drugs like semaglutide.
The UN agency has received reports of medication falsified to look like the diabetes and weight loss drug Ozempic in at least 3 countries, including the U.S.
Experts with the U.S. Preventive Services Task Force say not enough data has been collected to know whether newer obesity medications for teens are safe.
Americans pay $969 a month for Ozempic, while Canadians pay just $155.
Healthcare company Ro just launched a GLP-1 supply tracker. Eli Lilly is working on one, too
The results of the longest-running trial of semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, are here and looking positive.
The Vermont senator is launching an investigation into why these game-changing diabetes and obesity drugs can cost more than $1,000 a month in America.
New data from Eli Lilly suggests that Zepbound can help people lose weight and have fewer episodes of obstructive sleep apnea at the same time.
Some people fear that new obesity drugs will inevitably prove to be dangerous, but there are key distinctions from the fen-phen crisis of the 1990s.
Roughly 42% of Americans are obese, making the U.S. a huge market for anti-obesity drugs.
In a new Oscar-themed commercial, the drugmaker is telling people to stay away from its blockbuster medications if they’re only looking to lose a few pounds.
Zepbound (tirzepatide) had striking effects on blood pressure in the latest trial data, in addition to helping people shed pounds.
